Lexicon Pharmaceuticals (Nasdaq: LXRX) and Novo Nordisk announced initiation of a Phase 1 study of LX9851, an oral non-incretin candidate for obesity.
Lexicon earned a second $10 million milestone in 2026, may earn a third this year, and is eligible for up to $1 billion in total payments plus tiered royalties. The 96-subject trial is expected to complete in Q1 2027.
Loading…
Loading translation…
Positive
Second $10M milestone earned following initial Phase 1 dosing
Eligible for up to $1B in upfront and milestone payments
Tiered royalties on net sales provide upside if commercialized
Phase 1 initiated with 96 people with overweight or obesity
Trial completion targeted in Q1 2027
Negative
Early-stage program (Phase 1): efficacy and safety in larger populations unproven
Material commercial payments depend on future development and sales milestones
+5.13%
News Effect
+$32M
Valuation Impact
$661M
Market Cap
0.0x
Rel. Volume
On the day this news was published, LXRX gained 5.13%, reflecting a notable positive market reaction.
Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
This price movement added approximately $32M to the company’s valuation, bringing the market cap to $661M at that time.
Data tracked by StockTitan Argus on the day of publication.
Near-term milestone
$10 million
Second milestone payment earned from Novo Nordisk in 2026
Potential near-term milestone
$10 million
Third milestone payment that may be achieved later in 2026
Total potential payments
$1 billion
Maximum upfront and milestone payments under LX9851 collaboration
Phase 1 sample size
96 people
Participants with overweight or obesity in LX9851 Phase 1 study
Study completion timing
Q1 2027
Expected completion of LX9851 Phase 1 trial
Dose design
Single and multiple ascending doses
LX9851 Phase 1 design versus placebo
Potential milestone tranches
Three $10 million milestones
Series of near-term milestones tied to LX9851 development
Study population
Overweight or obesity
Target population for LX9851 Phase 1 investigation
$1.72
Last Close
Volume
Volume 6,237,288 is 2.27x the 20-day average of 2,753,285, indicating elevated trading interest ahead of this news.
high
Technical
Price at $1.56 is trading above the 200-day MA of $1.26, despite a -3.7% move over the prior day.
LXRX fell 3.7% pre-news with high volume. Peers showed mixed moves: FULC -3.84%, INBX -4.65%, SLDB -5.76%, while ATXS rose 0.8%. Momentum data show both up and down moves across names, pointing to stock-specific dynamics rather than a clean sector-wide trend.
Date
Event
Sentiment
Move
Catalyst
Jan 21
End-of-Phase 2 FDA
Positive
+19.1%
FDA raised no objections to advancing pilavapadin into Phase 3.
Dec 05
HFpEF adipose data
Neutral
-1.4%
Presentation of sotagliflozin adipose distribution data at CVCT 2025.
Nov 08
HFpEF efficacy data
Positive
+13.6%
Statistically significant HFpEF benefits without diabetes in SOTA P CARDIA trial.
Mar 03
Phase 2b PROGRESS topline
Negative
-58.2%
PROGRESS met objectives but missed primary endpoint statistical significance.
Mar 02
PROGRESS results preview
Neutral
-58.2%
Announcement of upcoming Phase 2b PROGRESS topline results webcast.
Pattern Detected
Clinical trial headlines have produced volatile moves for LXRX, including both strong rallies and sharp drawdowns, showing that data and regulatory nuances materially sway reactions.
Recent Company History
Over the past year, Lexicon’s story has centered on clinical and regulatory progress across multiple programs. Clinical-trial news included positive HFpEF data for sotagliflozin and an End-of-Phase 2 FDA meeting clearing pilavapadin for Phase 3 design talks, alongside a sharply negative reaction to Phase 2b PROGRESS topline results. Today’s LX9851 Phase 1 initiation builds on that pipeline narrative and follows the 10-K’s description of LX9851’s licensing to Novo Nordisk with substantial potential milestone and royalty economics.
-17.0%
Average Historical Move
clinical trial
In the last 12 months, Lexicon issued 5 clinical-trial headlines averaging a -17.01% next-day move, with both strong gains and steep losses. The LX9851 Phase 1 start continues this pattern of market sensitivity to clinical updates.
Clinical news shows progression from Phase 2b pilavapadin data to an End-of-Phase 2 FDA meeting, plus expanding sotagliflozin datasets, now complemented by LX9851’s transition into Phase 1 under Novo Nordisk.
The stock moved +5.1% in the session following this news. A strong positive reaction aligns with the significance of a first-in-class obesity candidate entering Phase 1 under a major partner. Past clinical headlines produced large moves, including both rallies and steep declines, so volatility around LX9851 updates would not be unusual. Investors could weigh the $10 million milestones and eligibility for up to $1 billion in payments against trial execution risk and broader biotech sentiment.
phase 1
medical
“Novo Nordisk has initiated a Phase 1 study with LX9851, a first-in-class…”
Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.
placebo
medical
“doses of LX9851 compared to placebo in 96 people with overweight or obesity.”
A placebo is an inactive pill, injection or procedure that looks and feels like the real treatment but contains no therapeutic ingredient, often called a sugar pill. Investors care because comparing a drug to a placebo reveals whether observed benefits come from the medicine itself or from expectation; clear superiority over placebo reduces regulatory and commercial risk, much like a blind taste test proves a new recipe really tastes better.
pharmacokinetics
medical
“investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of…”
Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.
pharmacodynamics
medical
“safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple…”
Pharmacodynamics is how a drug actually affects the body — the strength, type and duration of its effects and the relationship between dose and response. Think of it like how turning a thermostat changes room temperature: it shows what the drug does and how much is needed to get the desired effect. Investors care because these properties drive clinical success, dosing convenience, safety profile and competitive advantage, all of which influence commercial potential and regulatory approval.
non-incretin
medical
“LX9851 is a first-in-class, oral non-incretin candidate being developed…”
Non-incretin describes a drug, treatment, or biological effect that works without involving incretins—gut hormones (such as GLP‑1) that help control insulin and blood sugar. For investors, labeling a therapy non-incretin signals a different mechanism of action, which can mean distinct safety, effectiveness, regulatory hurdles and market positioning; think of it as choosing a different engine type with its own costs, benefits and customer niche.
AI-generated analysis. Not financial advice.
03/23/2026 – 07:30 AM
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders
Lexicon has earned a second of three potential $10 million near-term milestone payments and is eligible to receive up to $1 billion in total upfront and milestone payments from the collaboration, plus royalties on net sales
THE WOODLANDS, Texas, March 23, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) and Novo Nordisk A/S today announced that Novo Nordisk has initiated a Phase 1 study with LX9851, a first-in-class, oral non-incretin development candidate.
In March 2025, Lexicon signed an exclusive license agreement with Novo Nordisk for LX9851 in obesity and associated metabolic disorders. Under the terms of the agreement, Novo Nordisk obtained an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications.
Lexicon has earned a second $10 million milestone payment in 2026 from Novo Nordisk following initial dosing requirements in the Phase 1 study and is eligible for a third $10 million milestone payment that may be achieved later this year. In total, Lexicon is eligible to receive up to $1 billion in upfront and potential development, regulatory and sales milestone payments. Lexicon is also entitled to tiered royalties on net sales of LX9851.
“We are thrilled with the progress of the Novo Nordisk team on initiating the clinical development of LX9851,” said Mike Exton, CEO and director of Lexicon. “The talented team at Novo Nordisk has recognized the significant potential for LX9851, a novel, oral candidate for obesity and has moved swiftly to advance the program in its pipeline. We believe LX9851 has the potential to become a differentiated approach in the next phase of treatments for obesity and metabolic disease.”
“We are excited about the potential of LX9851 and pleased to take it into clinical testing to further explore the potential of the candidate,” said Jacob Sten Petersen, Senior Vice President and Head of Global Research at Novo Nordisk. “LX9851 offers a novel approach to the treatment of obesity and related metabolic conditions. It is an important addition to our pipeline of potential treatment options as we look to meet the diverse needs of people living with obesity, diabetes and their associated comorbidities.”
The Phase 1 study is investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of LX9851 compared to placebo in 96 people with overweight or obesity. The trial is expected to be completed in the first quarter of 2027.
About LX9851
LX9851, discovered by Lexicon and in development by Novo Nordisk, is a potent and selective oral small molecule inhibitor of Acyl CoA Synthetase 5 (ACSL5). ACSL5 plays a key role in the metabolic pathway which regulates fat accumulation and energy balance. Additionally, LX9851 may activate the ileal brake mechanism leading to increased satiety by delaying gastric emptying and suppressing appetite. Preclinical in vivo efficacy data presented at Obesity Week 2024 show that LX9851, when combined with semaglutide, significantly reduced weight, food intake and fat mass compared to semaglutide alone. Separately, LX9851 mitigated weight regain and had positive effects on liver steatosis when introduced after semaglutide discontinuation.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to the preclinical and clinical development of LX9851, Lexicon’s financial position and long-term outlook on its business, growth and future operating results, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2025 and other subsequent disclosure documents filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
FAQ
What did Lexicon (LXRX) and Novo Nordisk announce on March 23, 2026 about LX9851?
They announced initiation of a Phase 1 study for LX9851, an oral non-incretin candidate for obesity. According to the company, the trial will enroll 96 people and assesses safety, tolerability, pharmacokinetics and pharmacodynamics.
How much milestone money has Lexicon (LXRX) received related to LX9851 so far in 2026?
Lexicon has earned a $10 million milestone payment in 2026 tied to initial dosing in the Phase 1 study. According to the company, a third $10 million milestone may be achieved later this year.
What is the total financial upside for Lexicon (LXRX) from the Novo Nordisk collaboration on LX9851?
Lexicon is eligible to receive up to $1 billion in upfront and potential development, regulatory and sales milestone payments. According to the company, Lexicon will also earn tiered royalties on net sales.
What are the design and timeline details of the LX9851 Phase 1 trial (LXRX)?
The Phase 1 trial is a single and multiple ascending dose study vs placebo in 96 people with overweight or obesity. According to the company, the trial is expected to complete in Q1 2027.
Does the Phase 1 start for LX9851 (LXRX) indicate commercial readiness?
No, Phase 1 initiation indicates early clinical testing focused on safety and PK, not commercialization. According to the company, further trials and milestones are required before any regulatory approvals or sales.
What rights did Novo Nordisk obtain under the LX9851 license with Lexicon (LXRX)?
Novo Nordisk obtained an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in obesity and related metabolic disorders. According to the company, Lexicon retains eligibility for milestones and royalties.